- Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
- Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
- New penicillin production process will significantly improve ecological footprint and help secure European-based supply
- Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business
Basel – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.
Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The EUR 150 million Kundl investment, which includes a contribution of EUR 50 million from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.
Richard Saynor, CEO Sandoz said: "These investments strengthen our industrial presence in Europe, reinforce our commitment to environmental responsibility, and reaffirm our determination to be the world's leading and most valued generics and biosimilars company. Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing. The new development center in Holzkirchen will become a global hub for biosimilar expertise."
The EUR 25 million Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.
The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring availability of medicines and advancing medical research in Europe.
Air Products to Build Europe’s Largest Blue Hydrogen Plant and Strengthens Long-term Agreement in Rotterdam, The Netherlands
The facility is expected to be on-stream in 2026, and the resulting "blue" hydrogen product to serve ExxonMobil’s (Esso) Rotterdam refinery and additional customers via Air Products' hydrogen pipel...
OMV and Interzero establish joint venture to build and operate Europe’s largest sorting facility for chemical recycling in Walldürn, Germany
innovative, fully automatic, sorting plant with capacity of up to 260,000 tonnes per year. Mixed plastics into feedstock for OMV’s chemical recycling. Investment volume over EUR 170 mn
Carbios obtains building and operating permits, in line with announced schedule, for world’s first PET biorecycling plant in Longlaville, France
This authorization allows construction work to start as planned for the plant’s commissioning in 2025. The plant will have a capacity of 50,000 tons of PET waste and will create 150 jobs
Fluor Awarded FEED Contract for World’s First Industrial-Scale Sodium-Ion Battery Production Facility in Sandviken, Sweden
We are thrilled that Altris turned to Fluor to help them bring this cutting-edge technology to market that will transform manufacturing to be safer and more sustainable.